Results 51 to 60 of about 86,105 (313)

Effects of rifampin on the pharmacokinetics and pharmacodynamics of milvexian, a potent, selective, oral small molecule factor XIa inhibitor

open access: yesScientific Reports, 2022
Milvexian (BMS-986177/JNJ-70033093) is a potent, oral small molecule that inhibits the active form of factor XI with high affinity and selectivity.
Vidya Perera   +8 more
doaj   +1 more source

Genome-Wide Transposon Screen of a Pseudomonas syringae mexB Mutant Reveals the Substrates of Efflux Transporters. [PDF]

open access: yes, 2019
Bacteria express numerous efflux transporters that confer resistance to diverse toxicants present in their environment. Due to a high level of functional redundancy of these transporters, it is difficult to identify those that are of most importance in ...
Deutschbauer, Adam M   +4 more
core   +1 more source

Efficacy of Three-Week Oxytetracycline or Rifampin Monotherapy Compared with a Combination Regimen against the Filarial Nematode Onchocerca ochengi [PDF]

open access: yes, 2014
Onchocerciasis (river blindness), caused by the filarial nematode Onchocerca volvulus, is a major cause of visual impairment and dermatitis in sub-Saharan Africa. As O.
Bah, Germanus S   +5 more
core   +1 more source

Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. [PDF]

open access: yes, 2020
BACKGROUND: Buruli ulcer is a neglected tropical disease caused by Mycobacterium ulcerans infection that damages the skin and subcutis. It is most prevalent in western and central Africa and Australia.
Abass, KM   +31 more
core   +3 more sources

Role of Rifampin against Staphylococcal Biofilm Infections In Vitro, in Animal Models, and in Orthopedic-Device-Related Infections

open access: yesAntimicrobial Agents and Chemotherapy, 2018
Rifampin has been used as an agent in combination therapy in orthopedic device-related infections (ODRI) for almost three decades. The aim of this review is to provide data regarding the role of rifampin against biofilm infection in vitro, in animal ...
W. Zimmerli, P. Sendi
semanticscholar   +1 more source

In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant acinetobacter baumannii [PDF]

open access: yes, 2019
Carbapenem-resistant Acinetobacter baumannii (CR-Ab) infections are associated with high morbidity and mortality. The aim of the study was to evaluate the in-vitro activity of different antimicrobial combinations (with and without colistin, COL) against ...
De Angelis, Massimiliano   +6 more
core   +1 more source

Safety and Side Effects of Rifampin versus Isoniazid in Children

open access: yesNew England Journal of Medicine, 2018
BACKGROUND The treatment of latent infection with Mycobacterium tuberculosis is important in children because of their vulnerability to life‐threatening forms of tuberculosis disease.
T. Diallo   +20 more
semanticscholar   +1 more source

A Case of Acquired Rifampin Resistance in Mycobacterium bovis Bacillus Calmette-Guérin-Induced Cystitis: Necessity for Treatment Guidelines

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, 2006
A case of presumed bacillus Calmette-Guérin (BCG) cystitis in an elderly female patient following direct intravesical BCG instillation treatment for papillary transitional cell carcinoma is reported.
Joyce N Wolfe   +3 more
doaj   +1 more source

Penicillin Use in Meningococcal Disease Management: Active Bacterial Core Surveillance Sites, 2009. [PDF]

open access: yes, 2016
In 2009, in the Active Bacterial Core surveillance sites, penicillin was not commonly used to treat meningococcal disease. This is likely because of inconsistent availability of antimicrobial susceptibility testing and ease of use of third-generation ...
Anderson, Raydel   +18 more
core   +2 more sources

Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis [PDF]

open access: yes, 2015
Supported by the Global Alliance for TB Drug Development with support from the Bill and Melinda Gates Foundation, the European and Developing Countries Clinical Trials Partnership, U.S. Agency for International Development, U.K.
Crook, Angela M.   +9 more
core   +1 more source

Home - About - Disclaimer - Privacy